Physician Assistant
Audio Summaries

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

This study aimed to evaluate the safety, tolerability, and preliminary efficacy of AC01, an oral ghrelin receptor agonist, in patients with heart failure with reduced ejection fraction (HFrEF). The results indicated that AC01 was generally safe and well tolerated over 28 days, with no major adverse events reported, suggesting potential for further investigation in larger trials.

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis

The authors aimed to evaluate the efficacy and safety of a 6-month treatment regimen for pulmonary rifampicin-resistant tuberculosis compared to the standard 9-month treatment in South Africa. The study found that the 6-month regimen was noninferior in achieving successful treatment outcomes and had a similar safety profile to the standard regimen. This suggests that the shorter treatment duration may be a viable alternative for managing rifampicin-resistant tuberculosis.

Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial

The authors aimed to evaluate the efficacy and safety of tirofiban, a glycoprotein IIb/IIIa receptor antagonist, in improving functional independence in patients with acute ischaemic stroke following successful endovascular reperfusion. In a multicentre, double-blind, randomized controlled trial involving 1,380 patients, tirofiban was found to significantly increase the likelihood of functional independence at 90 days compared to placebo, although there was no significant difference in the rates of symptomatic intracranial hemorrhage or mortality between the two groups.

Prevention and Treatment of Peanut Allergy

This paper investigates the effectiveness of early peanut protein introduction and immunotherapy in preventing and treating peanut allergy. The authors find that introducing peanut protein early significantly reduces allergy prevalence, with optimal prevention strategies differing for low and high-risk infants. Additionally, they highlight that immunotherapy is more effective when started in younger children, emphasizing the critical need for early intervention.

Assessing early effects of Australia's Social Media Minimum Age Act on adolescents' social media use: observational study

The study aimed to assess the early effects of Australia's Social Media Minimum Age Act 2024, which set a minimum age of 16 for social media accounts, on adolescents' social media use. Findings indicated that while many adolescents under 16 continued to use social media, with some reporting attempts to circumvent age verification, there was no significant reduction in overall social media use among this group. The results suggest that the Act has not yet achieved its intended goal of delaying access to social media for younger adolescents.

Self-Directed vs Clinician-Delivered Cognitive Behavioral Therapy for Chronic Pain: A Randomized Clinical Trial

The authors aimed to compare the effectiveness of self-directed cognitive behavioral therapy for chronic pain (CBT-CP) with asynchronous feedback to clinician-delivered CBT-CP in patients with chronic musculoskeletal pain. The study found that self-directed CBT-CP significantly reduced pain interference and improved secondary outcomes at 4 months, with benefits sustained at 12 months, suggesting it may be a more accessible alternative to traditional clinician-delivered therapy.

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

The authors aimed to evaluate the long-term outcomes of anti-CD19 CAR T-cell therapy (tisagenlecleucel) in patients with relapsed or refractory B-cell non-Hodgkin lymphomas over a median follow-up of 10.1 years. They found that approximately 32% of patients with large B-cell lymphoma and 47% with follicular lymphoma achieved lymphoma-free survival, with a notable persistence of B-cell aplasia in long-term responders. The study highlights the potential for durable remissions in this patient population, despite some risks of non-relapse-related mortality and secondary cancers.

Combined bladder-kidney transplantation: first-in-human feasibility trial

The authors investigate the feasibility and safety of combined bladder-kidney transplantation as a novel treatment for patients with terminal bladder dysfunction and end-stage kidney disease. The first-in-human trial demonstrated successful surgical outcomes, with the patient maintaining good renal and bladder function, sensation, and continence beyond six months post-transplantation, suggesting this approach may be a viable option for select patients requiring immunosuppression.

Non-invasive removal of the Smart tracheal occlusion device for fetal congenital diaphragmatic hernia: a single-arm, open-label, phase 1 study

This study aimed to evaluate the effectiveness and safety of a novel non-invasive tracheal occlusion device (Smart-TO) for treating congenital diaphragmatic hernia (CDH) in fetuses, which eliminates the need for a second intervention to restore airway patency. The results demonstrated a 100% deflation rate of the device using magnetic resonance imaging, with all infants having the balloon successfully expelled from their airways at birth, indicating a significant advancement in fetal surgery for CDH. Overall, the findings suggest that the Smart-TO device is effective and safe for use in this clinical context.

Apolipoprotein L1 Gene Genotype and Kidney Outcomes After Living Kidney Donation

The authors aimed to investigate the association between apolipoprotein L1 gene (APOL1) polymorphisms and kidney function outcomes following living kidney donation. Their findings indicate that Black kidney donors with high-risk APOL1 genotypes are at a significantly increased risk of developing reduced kidney function post-donation, suggesting that APOL1 genotyping should be considered for Black living donor candidates to improve risk assessment.